Anti-HCV agent, ribavirin, elevates the activity of clotting factor VII in patients with hemophilia: A possible mechanism of decreased events of bleeding in patients with hemophilia by ribavirin [1]

Journal of Thrombosis and Haemostasis

Volumn 4, Issue 2, 2006, Pages 469-470

  Yamamoto, Koji ^a   Honda, T ^b   Matsushita, T ^b   Kojima, T ^c   Takanatsu, J ^a  

^a NAGOYA UNIVERSITY HOSPITAL   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 7; PROTHROMBIN; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; ANTIVIRUS AGENT; MESSENGER RNA;

ADULT; BLEEDING; BLOOD CLOTTING; BLOOD LEVEL; CELL CULTURE; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DRUG MECHANISM; DRUG RESPONSE; GENE EXPRESSION; GENE LOCATION; HEMOPHILIA; HEMOPHILIA A; HEMOPHILIA B; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LETTER; LIVER BIOPSY; LIVER FUNCTION; PRIORITY JOURNAL; STATISTICAL ANALYSIS; BIOSYNTHESIS; BLOOD; DRUG EFFECT; GENETICS; HEPATITIS C VIRUS; LIVER CELL; MALE; METABOLISM; MIDDLE AGED;

ADULT; ANTIVIRAL AGENTS; CELLS, CULTURED; FACTOR VII; GENE EXPRESSION; HEMOPHILIA A; HEMOPHILIA B; HEPACIVIRUS; HEPATITIS C, CHRONIC; HEPATOCYTES; HUMANS; MALE; MIDDLE AGED; RIBAVIRIN; RNA, MESSENGER;

EID: 33645566188     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2006.01761.x     Document Type: Letter

References (10)

1. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 1485-92.
2. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2001; 358: 958-65.
3. Santagostino E, Rumi MG, Rivi M, Colombo M, Mannucci PM. Sustained suppression of hepatitis C virus by interferon and ribavirin in hemophilic patients not responding to interferon monotherapy. Blood 2002; 99: 1089-91.
4. Honda T, Toyoda H, Hayashi K, Katano Y, Yano M, Nakano I, Yoshioka K, Goto H, Yamamoto K, Takamatsu J. Ribavirin and the use of clotting factors in patients with hemophilia and chronic hepatitis C. JAMA 2005; 293: 1190-2.
5. Schulman S. Inhibition of warfarin activity by ribavirin. Ann Pharmacother 2002; 36: 72-4.
6. Morrissey JH, Macik BG, Neuenschwander PF, Comp PC. Quantitation of activated factor VII in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood 1993; 81: 734-44.
7. Roberts HR, Monroe DM, Oliver JA, Chang JY, Hoffman M. Newer concepts of blood coagulation. Haemophilia 1998; 4: 331-4.
8. Roberts HR, Monroe DM, White GC. The use of recombinant factor VIIa in the treatment of bleeding disorders. Blood 2004; 104: 3858-64.
9. Junker R, Heinrich J, Schulte H, van de Loo J, Assmann G. Coagulation factor VII and the risk of coronary heart disease in healthy men. Arterioscler Thromb Vasc Biol 1997; 17: 1539-44.
10. Lowe GD, Rumley A, McMahon AD, Ford I, O'Reilly DS, Packard CJ for the West of Scotland Coronary Prevention Study Group. Interleukin-6, fibrin D-dimer, and coagulation factors VII and XIIa in prediction of coronary heart disease. Arterioscler Thromb Vasc Biol 2004; 24: 1529-34.